AIM ImmunoTech Announces Positive Safety Data from the Third Cohort of Its Phase 1 Intranasal Clinical Trial - BioSpace Get link Facebook X Pinterest Email Other Apps May 26, 2021 AIM ImmunoTech Announces Positive Safety Data from the Third Cohort of Its Phase 1 Intranasal Clinical Trial BioSpace Get link Facebook X Pinterest Email Other Apps Comments
Comments
Post a Comment